At 3.5% CAGR, the Europe Helicobacter Pylori (H. pylori) Non-invasive Testing Market is projected to be worth US$ 244.01 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe helicobacter pylori (H. pylori) non-invasive testing market was valued at US$ 198.40 million in 2022 and is expected to reach US$ 244.01 million by 2028, registering an annual growth rate of 3.5% from 2022 to 2028. Increasing prevalence of H. pylori bacterial infection and new product launches & FDA approvals for noninvasive tests are the critical factors attributed to the market expansion.

About 50% of the population is infected by H. pylori infection. The infection is usually developed during infant but remains asymptomatic, with long-standing clinical symptoms including gastritis, peptic ulcer disease, and stomach cancer.

Also, according to World Health Organization (WHO), developing countries have about 90% high prevalence rate in developing countries, whereas, in developed countries, the prevalence rate is low, i.e., 50%. The H. pylori infection rate in females was found to be 42.7% as compared to 46.3% in males. Moreover, it was significantly higher in adults than in children, 48.6% and 32.6%, respectively.

Further, the prevalence of the gastric disease is significantly higher in the geriatric population as aging increases the risk of H. pylori infection. Increased age leads to thinning of the stomach lining, thus allowing the bacteria to pass through the protective lining that contributes to the growing prevalence of infection among older people. With the subsequent increase in geriatric population, the demand for primary care services, including screening, assessment, and management of clinical and functional comorbidities, is increasing. These statistics determine an increase in the need for diagnostics in various regions across the region. Hence, boosting the growth of the Helicobacter pylori noninvasive testing market during the forecast period.    

On the contrary, very low diagnosis rate hurdles the growth of Europe helicobacter pylori (H. pylori) non-invasive testing market.

• Based on test type, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market in 2022 with a share of 45.2%, amassing US$ 9 89.76 million. It is projected to garner US$ 113.31 million by 2028 to expand at 4.0% CAGR during 2022–2028.
• Based on test method, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022 with a share of 75.2%, amassing US$ 149.27 million. It is projected to garner US$ 185.99 million by 2028 to expand at 3.7% CAGR during 2022–2028.
• Based on end user, the Europe Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022 with a share of 58.9%, amassing US$ 116.78 million. It is projected to garner US$ 145.48 million by 2028 to expand at 3.7% CAGR during 2022–2028.

Our regional analysis states that Germany captured 21.4% market share in 2022. It was assessed at US$ 42.38 million in 2022 and is likely to hit US$ 49.66 million by 2028, exhibiting a CAGR of 2.7% during the forecast period.

Key players dominating the Europe helicobacter pylori (H. pylori) non-invasive testing market are Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc.

Below are mentioned a few key market developments by major players:

• In Dec 2021, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.

• In April 2020, Meridian Bioscience, Inc. has completed the acquisition of Exalenz Bioscience Ltd., the Modiin, Israel-based provider of the BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com